On April 22, 2026 BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer, reported new preclinical data presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, highlighting the discovery and characterization of its lead pan-KRAS inhibitor, BH-501284, along with additional updates across its pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Despite recent advances, patients with KRAS-driven tumors continue to face limited and often short-lived treatment options. Our mini-symposium presentation at AACR (Free AACR Whitepaper) introduces our differentiated pan-KRAS inhibitor, BH-501284, with pre-clinical data demonstrating the potential for this molecule to deliver broad and durable pathway inhibition across multiple KRAS-driven tumors," said Jean Cui, Ph.D., Founder and Chief Executive Officer of BlossomHill Therapeutics. "We are particularly encouraged by the depth and consistency of activity observed across models, including sustained target engagement and tumor regression at low dose levels. Based on these results, we are advancing IND-enabling studies for BH-501284 and preparing for clinical development."

Data presented in the AACR (Free AACR Whitepaper) Mini Symposium provides pre-clinical data supporting BH-501284 as a novel, orally available, non-covalent, pseudo-irreversible pan-KRAS inhibitor designed to overcome limitations of current KRAS-targeted therapies.

Key findings from the mini symposium titled "Discovery and characterization of BH-501284: A non-covalent, pan-KRAS inhibitor for treatment of diverse KRAS-mutant tumors" include:

Median IC50 of 0.83 nM across 41 different G12/G13 KRAS mutant cell lines (excluding G12R), but sparing HRAS and NRAS (>650 nM) to avoid the toxicity of pan-RAS inhibitors
Picomolar binding affinity and prolonged residence time (>54 hours) mirroring the binding of covalent inhibitors but with a non-covalent, pseudo-irreversible chemistry leading to prolonged inhibition of KRAS signaling
Deep tumor regression in multiple KRAS-mutant xenograft models achieved at lower doses (5-15 mg/kg BID) compared to what has been reported with other contemporary Switch-II pocket inhibitors
The company also presented a poster describing the preclinical characterization of additional molecules within the pan-KRAS program (BH-501242, BH-501352), in which BH-501242 demonstrated cellular potency exceeding that of comparator molecules, and both molecules demonstrated prolonged non-covalent binding, and favorable absorption, distribution, metabolism and excretion (ADME) properties.

Additional AACR (Free AACR Whitepaper) Posters from the BlossomHill Therapeutics Pipeline

BH-30643 (Mutant-selective EGFR inhibitor)
Poster: "BH-30643, a novel macrocyclic non-covalent, mutant-selective EGFR inhibitor, addresses the resistance and potency limitations of contemporary EGFR TKIs"

Potent and durable inhibition across diverse EGFR-mutant models, including C797S and T790M
Maintained low nanomolar potency in presence of EGFR ligands
Showed prolonged suppression of tumor cell growth compared to approved EGFR TKIs
Induced deep tumor regression across multiple in vivo models, including intracranial models
Sustained suppression of EGFR signaling in dose- and time-dependent manner
Findings support potential of BH-30643 to overcome key limitations of current therapies
BH-30236 (CLK inhibitor for hematologic malignancies)
Poster: "CLK inhibitor BH-30236 synergizes with venetoclax in anti-leukemia activity via splicing modulation in preclinical AML and CLL models"

Broad anti-proliferative activity through modulated mRNA splicing
Reduced expression of pro-survival factors, leading to activation of apoptosis and DNA damage response pathways
Consistent synergy with venetoclax across multiple blood cancer models
Induced tumor regression in resistant acute myeloid leukemia (AML) xenografts, including complete responses
Sustained tumor-free survival following treatment discontinuation, consistent with effects on leukemia stem cell populations
Findings support continued clinical development of BH-30236 as both a monotherapy and in combination regimens

(Press release, BlossomHill Therapeutics, APR 22, 2026, View Source [SID1234664713])

On April 22, 2026 Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, reported the nationwide availability of Agilent Technologies’ PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck’s KEYTRUDA.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Helping Patients Access Critical New Treatment Options
Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and poor survival outcomes. The approval of KEYTRUDA and KEYTRUDA QLEX in this setting introduces meaningful new treatment options that have been found to reduce the risk of disease progression and improve overall survival.iii Labcorp’s nationwide availability of PD-L1 IHC 22C3 pharmDx enables clinicians to quickly identify patients who may benefit from these newly approved treatments.

"Platinum-resistant ovarian cancer is incurable, and current treatment options offer limited and short-lived benefits for patients—making it one of the most challenging forms of the disease to treat," said Dr. Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp. "By making this companion diagnostic available nationwide, Labcorp is helping clinicians rapidly identify eligible patients and connecting them with a therapy that offers new hope."

Supporting Early Access Following FDA Approvals
Following the FDA’s February approval of KEYTRUDA and KEYTRUDA QLEX alongside PD-L1 IHC 22C3 pharmDx,ii Labcorp participated in Agilent Technologies’ Early Validation Program to help support rapid testing availability. Through standardized training and readiness activities, Labcorp was prepared to expand nationwide access quickly following approval.

(Press release, LabCorp, APR 22, 2026, View Source [SID1234664682])

On April 22, 2026 Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, reported the pricing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 64,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 10,750,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.001 per pre-funded warrant. The common stock and pre-funded warrants are being sold in combination with an accompanying common stock warrant to purchase one share of common stock (or pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $3.00 per share, is immediately exercisable from the date of issuance and will expire upon the earlier of (i) the fifth anniversary of the original issuance date and (ii) forty-five days following the Company’s public announcement of a successful data readout of its Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis ("MASH"). The combined offering price of each share of common stock and accompany common stock warrant is $3.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $2.999. The offering is expected to close on or about April 24, 2026, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Altimmune. The gross proceeds from the offering before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225 million. The public offering is subject to market and other conditions, and there can be no assurance as to whether or when the public offering may be completed.

Altimmune intends to use the net proceeds from this offering to fund its upcoming Phase 3 trial in MASH, as well as for working capital and general corporate purposes.

Leerink Partners and Barclays are acting as joint bookrunning managers for the offering. Titan Partners is acting as co-bookrunning manager for the offering.

The shares of common stock, pre-funded warrants, common stock warrants and shares of common stock issuable upon the exercise of the pre-funded warrants and common stock warrants are being offered by Altimmune pursuant to two effective shelf registration statements on Form S-3 that were previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on December 5, 2025 and March 13, 2025, respectively, and a related registration statement that was filed with the SEC on April 22, 2026 pursuant to Rule 462(b) under the Securities Act of 1933, as amended (and became automatically effective upon filing). The preliminary prospectus supplement and accompanying prospectuses relating to and describing the terms of the offering were filed with the SEC on April 22, 2026 and are available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement may be obtained, when available, by contacting Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected]; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at [email protected]; or by accessing the SEC’s website at www.sec.gov. Before you invest, you should read the preliminary prospectus supplement and accompanying prospectuses and other documents Altimmune has filed with the SEC that are incorporated by reference into the preliminary prospectus supplement and accompanying prospectuses for more complete information about Altimmune and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Altimmune, APR 22, 2026, View Source [SID1234664698])

On April 22, 2026 The US Food and Drug Administration (FDA) reported that it has extended by up to three months the target action date for its review of the biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) in combination with approved standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all currently approved US indications of Sarclisa intravenous (IV) formulation. The revised target action date for the FDA decision is July 23, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sanofi is committed to working closely with the FDA to bring this new advancement to patients and providers as quickly as possible. If approved, Sarclisa would be the first anticancer treatment to be administered through an on-body injector (OBI).

On March 26, 2026, the European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Sarclisa SC administered via both an OBI and manual injection for the treatment of MM patients across all currently approved indications and combinations for Sarclisa IV formulation in the EU. A final decision is expected in the coming months.

About Sarclisa
Sarclisa (isatuximab-irfc) has been approved in almost 60 countries across four indications for certain patients with newly diagnosed MM and relapsed or refractory MM. Sarclisa-based regimens have been prescribed to treat more than 60,000 patients worldwide.

At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need.

For more information on Sarclisa clinical studies, please visit www.clinicaltrials.gov.

(Press release, Sanofi, APR 22, 2026, View Source [SID1234664714])

On April 22, 2026 NETRIS Pharma, a clinical-stage oncology company targeting the netrin-1 / epithelial-to-mesenchymal transition (EMT) axis, reported that positive results from « LAPNET-01 » its phase 1b trial (NCT05546853) of NP137, were published in Nature (DOI: 10.1038/s41586-026-10436-4) :

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data show that in patients with pancreatic ductal adenocarcinoma (PDAC) with locally advanced PDAC (LAPC), treatment with NP137, the first-in-class anti-netrin1 monoclonal antibody, in combination with modified FOLFIRINOX (mFOLFIRINOX) as a first-line therapy achieved a median progression free survival (PFS) of 10.85 months, median overall survival (OS) of 16.43 months and a 23% conversion-to-surgery rate. In addition, a subset of patients with high tumor netrin-1 receptor neogenin expression showed a median PFS of 15.65 months, a 40% conversion-to-surgery rate and a 12-months OS rate of 100%.

« Achieving this early clinical efficacy in pancreatic ductal adenocarcinoma is very promising for patients who have limited options. The group of neogenin-high patients, where we saw dramatically extended PFS and OS is unprecedented and opens a path for personalized and potentially more effective treatments of this group of pancreatic cancer patients » said Gael Roth, MD, PhD, Professor in GI Oncology at Grenoble Alpes University Hospital, LAPNET-01 lead investigator and first author of the paper in Nature. « The LAPNET-01 data amply justify further development in pancreatic ductal adenocarcinoma ».

Patrick Mehlen, PhD, Chief Executive Officer of NETRIS Pharma, said :

While this is only a Phase 1b trial, we are thrilled to observe the strong PFS and OS being achieved in the neogenin-high PDAC patients in LAPNET-01; we are eager to confirm these results in a larger study. This marks the third Nature publication outlining the compelling scientific and mechanistic rationale for our anti-netrin1 strategy. LAPNET-01 data strongly support the clinically meaningful potential of targeting the netrin-1 / EMT axis to overcome the development of treatment resistance by PDAC, especially in neogenin-high patients. These exciting positive data will accelerate further development of NP137, the first-in-class anti-netrin1 monoclonal antibody. We are engaging with US and EU regulatory authorities as we design the development pathway for NP137 to treat PDAC and other solid tumors.

The next steps for NETRIS include initiation of a randomized, potentially registrational, phase 2 trial of NP137 in first-line metastatic PDAC, incorporating a neogenin IHC assay to help validate this test as a potential companion diagnostic. The development of NP137 is advancing in several other oncology indications including HCC and HNSCC.

About LAPNET-01
LAPNET-01 (NCT05546853) was a multicenter, open-label, phase 1b study promoted by Grenoble Alpes University Hospital and conducted across nine centers in France. Between March 2023 and June 2024, 43 patients with LAPC were enrolled to receive 14 mg/kg of NP137 administered every two weeks in combination with mFOLFIRINOX, for up to 12 cycles. The study population was representative of LAPC. At baseline, all patients were considered unresectable, including 2 with metastatic disease.

The LAPNET-01 trial was designed around the specific hypothesis that mFOLFIRINOX drives EMT-mediated resistance in LAPC and that concurrent netrin1 blockade with NP137 could mitigate this effect, thereby augmenting the depth and durability of response to chemotherapy.

Response and Disease Control
Among 41 evaluable patients assessed by RECIST 1.1, 12 achieved a confirmed partial response (ORR 29%; 95% CI 0.16–0.46), with a median duration of response of 9.02 months (95% CI 5.84–NR). 88% of patients experienced tumor shrinking.

Progression-Free and Overall Survival
Median PFS was 10.85 months at a median follow-up of 13.1 months (95% CI 10.03–15.61), with 6-month and 12-month PFS rates of 88% and 45%, respectively. Notably, patients with high tumor neogenin expression treated with mFOLFIRINOX+NP137 achieved a markedly superior median PFS of 15.65 months versus 10.22 months in the neogenin-low group (p=0.003).

Median OS was 16.43 months (95% CI 12.75–NR), with 6-month and 12-month OS rates of 91% and 62%, and 21 patients still alive at the data cut-off. Median OS was not yet reached in the neogenin-high group with a 12-months OS rate of 100% at the time of data cut-off.

These outcomes compare favorably to benchmark data from the NEOPAN trial, which reported median PFS of approximately 9.7 months and median OS of approximately 15.7 months with FOLFIRINOX alone in LAPC.

Conversion to Surgery
Ten of 43 intention-to-treat patients (23%) and four of 10 (40%) of neogenin-high patients underwent post-therapy R0 resection — a rate that is substantially higher than benchmark conversion rates from prospective LAPC trials.

Neogenin, Candidate Companion Diagnostic

Pre-planned exploratory analyses examined components of the netrin1 signaling pathway for associations with outcomes in LAPNET-01. NEO1, encoding neogenin — a netrin1 receptor previously shown to mediate the netrin1-driven epithelial-to-mesenchymal transition (EMT) and tumor progression in pancreatic cancer preclinical models — emerged as the most strongly correlated gene with improved efficacy outcomes in the non-refractory patient subset (n=21) with available transcriptomic data.

Clinical Safety

Safety was assessed in all 43 patients who received at least one dose of NP137 plus mFOLFIRINOX. While 100% of patients experienced at least one adverse event (AE) with a grade 3 and above adverse event rate of 37%, this profile was comparable to what is anticipated with the chemotherapy backbone alone.

Full details of the LAPNET-01 data are available in the Nature paper :

The aggregated body of evidence — spanning two prior Nature publications (Cassier et al. and Lengrand et al., see links below), the NETRIS AACR (Free AACR Whitepaper) 2026 posters (Poster #2445, #7489 and #0822, presented this week, on April 20), and today’s Nature 2026 manuscript — supports a coherent mechanistic hypothesis : netrin1, re-expressed by cancer cells as a survival mechanism, is a master upstream regulator of epithelial-to-mesenchymal transition (EMT), a central mechanism for the development of acquired resistance in many tumor types.

The absence of a pharmacological EMT inhibitor in the approved oncology arsenal — a gap explicitly noted by the Nature editors in the clinical briefing accompanying the 2023 publications — positions NP137 as a potential first-in-class agent addressing a mechanism of resistance that is orthogonal to debulking agents such as checkpoint inhibition, KRAS targeting, and antibody-drug conjugate strategies.

About LAPC
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, ranking as the fourth leading cause of cancer-related death globally, with a five-year survival rate below 5%. LAPC — a subset representing roughly 30% of PDAC cases at diagnosis — occupies a particularly difficult clinical niche because tumors at this stage are predominantly unresectable, yet lack distant metastases, rendering patients ineligible for both metastatic and curative-intent surgical protocols.

The current standard of care, FOLFIRINOX or gemcitabine-based combinations, yields a median PFS of 6–10 months and a median OS of approximately 12–17 months in LAPC (LAP-07, NEOPAN trials). Conversion-to-surgery rates under these regimens are low: prospective data from the NEOPAN and CONKO-007 trials report R0 resection rates of 6% and 18%, respectively, while PANOVA-3 reported 10.8% under gemcitabine/nab-paclitaxel.

(Press release, Netris Pharma, APR 22, 2026, View Source [SID1234664683])